Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “AMF”) charter, Innate...

The acquisition of the anti-C5aR, a first-in-class clinical-stage antibody, announced on June 2, 2017, is now finalized; The 3,343,748 new ordinary shares have been issued to Novo Nordisk A/S at a...

All proposed resolutions were voted according to management’s recommendations; Bpifrance Participations, represented by Maïlys Ferrere, and Pr. Jean-Charles Soria were appointed to the Supervisory...

Oral presentation on the dose-escalation part of a Phase I trial at the International Conference on Malignant Lymphoma (ICML) in Lugano; IPH4102 was evaluated in elderly and heavily pretreated...

Anti-C5a receptor (C5aR) is a first-in-class clinical-stage monoclonal antibody (mAb) targeting myeloid-derived suppressor cells (MDSC) and neutrophils in the tumor microenvironment; Innate Pharma...

Proposals to appoint Supervisory board members and renew members’ mandates at the Annual General Meeting. Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) will hold its Annual...

Complete safety results and updated clinical activity data will be presented at the ICML 2017 in Lugano in June; Preparation for cohort expansion part is ongoing. Innate Pharma SA (the “Company” -...

Cash, cash equivalents and financial assets of the Company amounted to €223.8 million* ; Additional clinical data expected later in 2017. Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421...

Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “AMF”) charter, Innate...

Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “AMF”) charter, Innate...